CSL signs U.S. government agreements to lower drug prices for Medicaid

• CSL signed agreements with the US government to lower US drug prices, including Medicaid pricing comparable to other developed countries.
• Newly launched therapies will be similarly priced across all US payers under the Health and Human Services agreement.
• An Onshoring Agreement with the Commerce Department supports a USD 1.5 billion Illinois manufacturing expansion, creating at least 300 jobs.
• The deals add certainty on US pricing exposure, including some Section 232 tariffs, with no expected material impact in fiscal 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSL Limited published the original content used to generate this news brief on August 31, 2026, and is solely responsible for the information contained therein.